Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium pyruvate inhalation - EmphyCorp

Drug Profile

Sodium pyruvate inhalation - EmphyCorp

Alternative Names: EmphyClear COPD Oral Spray; EmphyClear COPD/Asthma Spray; N115; N115 Non-Steroidal Nasal Spray; Rx N115 non-steroidal nasal spray

Latest Information Update: 14 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emphycorp
  • Class Antiasthmatics; Antifibrotics; Sodium compounds
  • Mechanism of Action Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Cystic fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Interstitial lung diseases
  • Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Clinical Phase Unknown COVID 2019 infections
  • No development reported Lung disorders

Most Recent Events

  • 07 Apr 2020 EmphyCorp has patent protection for inhaled sodium pyruvate for the treatment of multiple diseases in USA before April 2020
  • 07 Apr 2020 EmphyCorp has patent protection for inhaled sodium pyruvate for the treatment of Viral infections
  • 07 Apr 2020 EmphyCorp has patent pending for inhaled sodium pyruvate for the treatment of Lung diseases in USA before April 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top